Press Releases

Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board

SAN DIEGO, March 04, 2022 — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.

“Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided valuable insight and counsel to the board as well as our staff. He has been an exemplary leader through the challenges the company has faced and has been fair and unwavering in his support for Adamis,” said Adamis’ CEO and President, Dr. Dennis J. Carlo. “We admire Dick for his work ethic and wish him all the best in his retirement.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company’s ZIMHI™ (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For additional information about Adamis Pharmaceuticals, please visit and follow us on Twitter and LinkedIn.


Adamis Investor Relations
Robert Uhl
Managing Director
ICR Westwicke

Primary Logo

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.